Latest Intellia Therapeutics News & Updates

See the latest news and media coverage for Intellia. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Intellia Therapeutics (Intellia)

Clinical-stage genome editing company

intelliatx.com
Headquarters
Cambridge, United States
Founded year
2014
Company type
Public company
Number of employees
200–600
Industry
Pharmaceuticals

Last updated

Latest news about Intellia Therapeutics (Intellia)

In short: Intellia announced positive Phase 3 data for its HAE therapy lonvo-z and secured a $400 million loan to extend its cash runway into 2028.

Company announcements

Intellia

Intellia announces Q1 2026 financial results and updates

Includes positive Phase 3 lonvo‑z data, a rolling BLA filing, resumed nex‑z Phase 3 screening, and approximately $207 million raised, supporting operations into 2028.

Unlock all announcements with a

Media coverage

Seeking Alpha

Intellia upgraded at Evercore ISI on nex-z hypothesis (NTLA:NASDAQ)

Intellia Therapeutics (NTLA) stock jumps as Evercore ISI upgraded the company on a hypothesis behind...

Unlock all articles with a

Never miss news about Intellia

Track Intellia and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Intellia competitors & trending companies

Browse news for competitors to Intellia and other trending companies.